Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 39 min 47 sec ago

LifeWatch(TM) Receives FDA Clearance for Its Continuous Vital Signs Monitoring Service

Tue, 02/09/2016 - 12:57
ZUG, Switzerland , Feb. 9, 2016 (Healthcare Sales & Marketing Network) - LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer and provider of medical solutions and remote diagnostic monitoring services in the digital health market, is pleased to an...
Devices, Monitoring, FDA
LifeWatch AG, LifeWatch, Vital Signs Patch

Boston Scientific Announces Medicare Will Cover WATCHMAN(TM) Left Atrial Appendage Closure Device

Mon, 02/08/2016 - 23:51
CMS will cover percutaneous LAAC therapy for Medicare beneficiaries consistent with the FDA label when specific conditions are met MARLBOROUGH, Mass., Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) a...
Devices, Interventional, Cardiology, Reimbursement
Boston Scientific, WATCHMAN, LAAC, Left Atrial Appendage Closure

Angel Medical Systems Announces FDA Advisory Committee Meeting for Review of the AngelMed Guardian(R) System

Mon, 02/08/2016 - 20:02
Guardian System Designed to Address the Challenge of Patients Not Recognizing or Responding Quickly to Heart Attacks SHREWSBURY, N.J., Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- Angel Medical Systems Inc. has announced that the Circulato...
Devices, Cardiology, Monitoring, FDA
Angel Medical Systems, Guardian System, implantable cardiac monitor

Timothy Damadian Named President and CEO of FONAR

Mon, 02/08/2016 - 19:55
MELVILLE, NY--(Healthcare Sales & Marketing Network) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, announced today that effective February 11, 2016, Timothy Damadian, the elder son of Dr. Raymond V. Damadian, has been named President an...
Devices, Radiology, Personnel
Fonar Corp, magnetic resonance imaging

Rubicon Genomics Announces Distribution Agreement with Beckman Coulter Life Sciences for its ThruPLEX(R) Plasma-Seq Kits

Mon, 02/08/2016 - 19:49
ThruPLEX® Plasma-seq Kits Enable NGS Library Preparation from Cell-Free DNA for Liquid Biopsies for Cancer Research Learn More about ThruPLEX Plasma-seq and Other Rubicon Library Preparation Kits for Research Applications at the 2016 AGBT General Me...
Diagnostics, Distribution
Rubicon Genomics, Beckman Coulter, ThruPLEX, Plasma-seq

Global Blood Therapeutics Announces Changes to Board of Directors

Mon, 02/08/2016 - 15:46
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 -- (Healthcare Sales & Marketing Network) -- Global Blood Therapeutics, Inc. (GBT) (GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with signific...
Biopharmaceuticals, Personnel
Global Blood Therapeutics, sickle cell

Supernus Prevails in Oxtellar XR(R) ANDA Litigation

Mon, 02/08/2016 - 15:43
A Federal Court Finds Supernus Patents Valid and Actavis Infringing Two of Them ROCKVILLE, Md., Feb. 08, 2016 -- (Healthcare Sales & Marketing Network) -- Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company focused on developing an...
Biopharmaceuticals, Generics, Litigation
Supernus Pharmaceuticals, Actavis, Oxtellar XR, oxcarbazepine

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Mon, 02/08/2016 - 15:39
Program is the Second of the Company's In Vivo Protein Replacement Platform™ Programs to Enter Clinical Development RICHMOND, Calif., Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic ...
Biopharmaceuticals, FDA
Sangamo BioSciences, Mucopolysaccharidosis, In Vivo Protein Replacement

Astellas Names James Robinson President, Americas Operations

Mon, 02/08/2016 - 13:47
NORTHBROOK, Ill., Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka today announced the promotion of James Robinson as president, Americas Operations, for Astellas US LL...
Biopharmaceuticals, Personnel
Astellas Pharma

Via Surgical Ltd., Closes $6M Investment Led by Benslie Investment Group

Mon, 02/08/2016 - 13:42
AMIRIM, Israel, February 8, 2016 -- (Healthcare Sales & Marketing Network) -- Via Surgical Ltd., a leading developer of novel surgical fixation technologies for mesh placement in hernia repair, announced today the company has secured a $6M investment led ...
Devices, Surgery, Venture Capital
Via Surgical, FasTouch, Deployable Suture Fixation, hernia repair

BMC Medical Co., Ltd Wins Patent Infringement Litigation Against ResMed

Mon, 02/08/2016 - 13:37
BEIJING, Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- BMC Medical Co., Ltd has won a global patent infringement litigation action against ResMed Inc. The United States Patent and Trademark Office (USPTO) issued a series of judgments in con...
Devices, Litigation
BMC Medical Co, ResMed, sleep therapy

Atlas Genetics Gains CE Approval for First Product

Mon, 02/08/2016 - 13:33
Approval of Chlamydia test for marketing and sale in Europe BATH, England, February 8, 2016 -- (Healthcare Sales & Marketing Network) -- Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) mol...
Diagnostics, Regulatory
Atlas Genetics, Chlamydia, io CT test

STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication

Mon, 02/08/2016 - 13:28
PRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)--STENTYS (FR0010949404 — STNT) (Paris:STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces the first distribution a...
Devices, Interventional, Product Launch
STENTYS, Self-Apposing Stent, drug eluting stent

CTI BioPharma Provides Update On Investigational Agent Pacritinib

Mon, 02/08/2016 - 13:21
FDA Places Partial Clinical Hold on Pacritinib IND; Currently Enrolled Patients Benefiting from Pacritinib Can Continue Receiving Pacritinib Phase 3 Clinical Trial (PERSIST-2) Evaluating Pacritinib for Patients with Myelofibrosis and Platelet Counts of ...
Biopharmaceuticals, Oncology
CTI BioPharma, Pacritinib, myelofibrosis

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong